Non-steroidal anti-inflammatory drugs in prevention of gastric cancer - PubMed (original) (raw)
Review
Non-steroidal anti-inflammatory drugs in prevention of gastric cancer
Yun Dai et al. World J Gastroenterol. 2006.
Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) including cyclooxygenase 2 (COX-2) selective inhibitors, are potential agents for the chemoprevention of gastric cancer. Epidemiological and experimental studies have shown that NSAID use is associated with a reduced risk of gastric cancer although many questions remain unanswered such as the optimal dose and duration of treatment. The possible mechanisms for the suppressor effect of NSAIDs on carcinogenesis are the ability to induce apoptosis in epithelial cells and regulation of angiogenesis. Both COX-dependent and COX-independent pathways have a role in the biological activity of NSAIDs. Knowledge of how NSAIDs prevent neoplastic growth will greatly aid the design of better chemopreventive drugs and novel treatments for gastric cancer.
References
- Popiela T, Kulig J, Kolodziejczyk P, Sierzega M. Long-term results of surgery for early gastric cancer. Br J Surg. 2002;89:1035–1042. -PubMed
- Forman D, Morris E, Eastwood A, Kleijnen J. Guidelines for treatment of upper gastrointestinal cancer. Lancet. 2003;361:80. -PubMed
- Maruyama M. Treatment results of gastric cancer staged by the TNM classification. In: Maruyama M, Kimura K, editors. Review of clinical research in gastroenterology. Tokyo (Japan): Igaku-Shoin; 1998. p. 112.
- Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276–1280. -PubMed
- Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53:1322–1327. -PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials